Personalis Wins Key Medicare Coverage for Breast Cancer Test—Expands Access to Pre-Surgical Monitoring
Medicare Now Covers Monitoring of Neoadjuvant Therapy in Breast Cancer
Personalis, Inc. (NASDAQ: PSNL) has achieved a significant milestone with the Centers for Medicare & Medicaid Services (CMS) expanding coverage for its NeXT Personal minimal residual disease (MRD) test. This latest decision is Personalis’ fourth Medicare coverage win, but more notably, it allows the test to be used for real-time monitoring of patients with Stage II-III Triple-Negative Breast Cancer (TNBC) or HER2-positive (HER2+) breast cancer who are undergoing neoadjuvant therapy (NAT)—that is, treatment before surgery.
Coverage Decision Anchored by Strong Clinical Evidence
The expanded coverage is rooted in data from the PREDICT-DNA study, recently published in the Journal of Clinical Oncology. The study followed 227 patients across 24 leading US cancer centers and found that ultrasensitive circulating tumor DNA (ctDNA) monitoring with NeXT Personal was able to track treatment response far more accurately than traditional clinical metrics. Notably, Personalis’ test identified low levels of cancer that less sensitive approaches often miss, with nearly half of all ctDNA detections post-therapy registering below 100 parts per million (PPM). Such low-level traces could be critical for early intervention.
| Key Data from PREDICT-DNA Study | NeXT Personal | Traditional Metrics |
|---|---|---|
| Detection of Low-Level Cancer (ctDNA < 100 PPM) | Yes, nearly 50% of cases | Often missed |
| Number of Patient-Specific Variants Tracked | Up to ~1,800 | Limited |
| Prediction of Long-Term Outcomes | Outperforms traditional approaches | Less accurate |
NeXT Personal’s Ultrasensitivity Provides Clinicians with a New Tool
The ability to identify traces of cancer that exist at very low concentrations before surgery provides clinicians with actionable insights to adapt treatment plans. According to Personalis’ President and Chief Medical Officer, Dr. Richard Chen, the highly quantitative, ultrasensitive nature of NeXT Personal—able to track up to 1,800 patient-specific variants—gives physicians unprecedented resolution for monitoring therapy effectiveness. As neoadjuvant therapy becomes the standard of care in more breast cancer cases, having a tool of this sensitivity could shift the paradigm for how these diseases are actively managed.
Looking Forward: Implications for Cancer Management and Reimbursement
This Medicare expansion is more than a coverage milestone—it signals growing recognition for truly personalized cancer diagnostics. Clinicians can now use NeXT Personal to monitor therapy response ahead of surgery, instead of relying solely on post-surgical surveillance. However, as with all medical advances, the real-world rate of adoption will rely on continued clinical validation, favorable reimbursement, and integration into existing care pathways.
Personalis acknowledges potential risks, such as shifts in healthcare policy, future clinical data developments, and competition. Yet, this latest coverage determination continues to move precision oncology toward more adaptive, evidence-driven patient management.
Key Takeaway: Medicare Expansion Underscores Confidence in Advanced MRD Testing
Medicare’s endorsement adds a layer of validation to NeXT Personal’s utility for neoadjuvant therapy monitoring in tough-to-treat breast cancers. For investors and stakeholders, this milestone not only broadens reimbursement but also reinforces the case for advanced, ultrasensitive testing paving the future of precision cancer care. It will be important to track how quickly clinicians adopt NeXT Personal and how continued clinical results stack up as the field progresses.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI